St. Luke's Mid America Heart Institute, Kansas City (United States of America)
55
presentations
9
followers
3
more
presentations
in this session
Analysing the advantages of glucagon-like peptide-1 receptor agonists/sodium-glucose cotransporter 2 inhibitors in high vs. low cardiovascular disease risk